NL2014935B1 - T cell receptor like antibodies having fine specificity. - Google Patents

T cell receptor like antibodies having fine specificity. Download PDF

Info

Publication number
NL2014935B1
NL2014935B1 NL2014935A NL2014935A NL2014935B1 NL 2014935 B1 NL2014935 B1 NL 2014935B1 NL 2014935 A NL2014935 A NL 2014935A NL 2014935 A NL2014935 A NL 2014935A NL 2014935 B1 NL2014935 B1 NL 2014935B1
Authority
NL
Netherlands
Prior art keywords
antibody
hla
binding
peptide
amino acid
Prior art date
Application number
NL2014935A
Other languages
English (en)
Dutch (nl)
Other versions
NL2014935A (en
Inventor
Peled Kamar Mira
Denkberg Galit
Reiter Yoram
Beer Ilan
Sinik Keren
Teboul Yael (Elbaz)
Shperber Yael (Sery)
Erel Segal Reut
Original Assignee
Applied Immune Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL2014935A priority Critical patent/NL2014935B1/en
Application filed by Applied Immune Tech Ltd filed Critical Applied Immune Tech Ltd
Priority to EP24193198.9A priority patent/EP4488293A3/en
Priority to CA3220475A priority patent/CA3220475A1/en
Priority to PCT/IL2016/050599 priority patent/WO2016199140A1/en
Priority to JP2017563328A priority patent/JP7013243B2/ja
Priority to CN201680040163.XA priority patent/CN108025045B/zh
Priority to JP2017563331A priority patent/JP6912392B2/ja
Priority to CN201680039192.4A priority patent/CN107847569A/zh
Priority to MX2017015801A priority patent/MX394431B/es
Priority to US15/579,616 priority patent/US11001642B2/en
Priority to ES16739266T priority patent/ES2922236T3/es
Priority to KR1020187000504A priority patent/KR20180012851A/ko
Priority to CA2988270A priority patent/CA2988270A1/en
Priority to EP16739266.1A priority patent/EP3302538B1/en
Priority to CN202210030010.4A priority patent/CN114437217B/zh
Priority to CA2987889A priority patent/CA2987889A1/en
Priority to EP16734763.2A priority patent/EP3302537A1/en
Priority to SG10202007398PA priority patent/SG10202007398PA/en
Priority to AU2016276555A priority patent/AU2016276555B2/en
Priority to KR1020177037826A priority patent/KR20180011275A/ko
Priority to EP22154188.1A priority patent/EP4039270A1/en
Priority to PCT/IL2016/050600 priority patent/WO2016199141A2/en
Priority to CN202210349590.3A priority patent/CN114605547B/zh
Priority to AU2016276556A priority patent/AU2016276556C1/en
Priority to IL256178A priority patent/IL256178B2/en
Priority to MX2017015928A priority patent/MX2017015928A/es
Publication of NL2014935A publication Critical patent/NL2014935A/en
Application granted granted Critical
Publication of NL2014935B1 publication Critical patent/NL2014935B1/en
Priority to MX2022009493A priority patent/MX2022009493A/es
Priority to IL256177A priority patent/IL256177A/en
Priority to US17/317,824 priority patent/US12252547B2/en
Priority to JP2021113633A priority patent/JP7147018B2/ja
Priority to JP2022150286A priority patent/JP7376655B2/ja
Priority to AU2022268398A priority patent/AU2022268398A1/en
Priority to IL304821A priority patent/IL304821A/en
Priority to JP2023183842A priority patent/JP2024016092A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL2014935A 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity. NL2014935B1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.
CA3220475A CA3220475A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
PCT/IL2016/050599 WO2016199140A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
JP2017563328A JP7013243B2 (ja) 2015-06-08 2016-06-08 微細特異性を有する親和性結合体
CN201680040163.XA CN108025045B (zh) 2015-06-08 2016-06-08 具有高亲和性和优良特异性的类tcr抗体结合域的亲和性实体及其用途
JP2017563331A JP6912392B2 (ja) 2015-06-08 2016-06-08 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
CN201680039192.4A CN107847569A (zh) 2015-06-08 2016-06-08 具有优良特异性的类t细胞受体抗体
MX2017015801A MX394431B (es) 2015-06-08 2016-06-08 Entidades de afinidad que comprenden un dominio de unión de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.
US15/579,616 US11001642B2 (en) 2015-06-08 2016-06-08 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
ES16739266T ES2922236T3 (es) 2015-06-08 2016-06-08 Entidades de afinidad que comprenden un dominio de unión a anticuerpo similar a TCR con gran afinidad y buena especificidad y usos de las mismas
KR1020187000504A KR20180012851A (ko) 2015-06-08 2016-06-08 고 친화성 및 고 특이성을 가진 tcr-유사 항체 결합 도메인을 포함하는 친화성 엔티티 및 이의 용도
CA2988270A CA2988270A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
EP16739266.1A EP3302538B1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
CN202210030010.4A CN114437217B (zh) 2015-06-08 2016-06-08 具有类tcr抗体结合域的亲和性实体及其用途
CA2987889A CA2987889A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
EP16734763.2A EP3302537A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
EP24193198.9A EP4488293A3 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
SG10202007398PA SG10202007398PA (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
AU2016276555A AU2016276555B2 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
EP22154188.1A EP4039270A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
PCT/IL2016/050600 WO2016199141A2 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
CN202210349590.3A CN114605547B (zh) 2015-06-08 2016-06-08 具有类tcr抗体结合域的亲和性实体及其用途
AU2016276556A AU2016276556C1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
IL256178A IL256178B2 (en) 2015-06-08 2016-06-08 Entities with high affinity and fine binding specificity containing binding regions of T-cell receptor-like antibodies and their uses
MX2017015928A MX2017015928A (es) 2015-06-08 2016-06-08 Anticuerpos similares al receptor de celulas t que tienen una especificidad fina.
KR1020177037826A KR20180011275A (ko) 2015-06-08 2016-06-08 우수한 특이성을 가진 t 세포 수용체 유사 항체
MX2022009493A MX2022009493A (es) 2015-06-08 2017-12-06 Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.
IL256177A IL256177A (en) 2015-06-08 2017-12-07 T-cell receptor-like antibodies with subtle specificity
US17/317,824 US12252547B2 (en) 2015-06-08 2021-05-11 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
JP2021113633A JP7147018B2 (ja) 2015-06-08 2021-07-08 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
JP2022150286A JP7376655B2 (ja) 2015-06-08 2022-09-21 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
AU2022268398A AU2022268398A1 (en) 2015-06-08 2022-11-11 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
IL304821A IL304821A (en) 2015-06-08 2023-07-30 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
JP2023183842A JP2024016092A (ja) 2015-06-08 2023-10-26 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.

Publications (2)

Publication Number Publication Date
NL2014935A NL2014935A (en) 2016-12-12
NL2014935B1 true NL2014935B1 (en) 2017-02-03

Family

ID=54325627

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.

Country Status (13)

Country Link
US (2) US11001642B2 (OSRAM)
EP (4) EP3302538B1 (OSRAM)
JP (5) JP6912392B2 (OSRAM)
KR (2) KR20180012851A (OSRAM)
CN (4) CN114605547B (OSRAM)
AU (3) AU2016276555B2 (OSRAM)
CA (3) CA2988270A1 (OSRAM)
ES (1) ES2922236T3 (OSRAM)
IL (3) IL256178B2 (OSRAM)
MX (3) MX2017015928A (OSRAM)
NL (1) NL2014935B1 (OSRAM)
SG (1) SG10202007398PA (OSRAM)
WO (2) WO2016199141A2 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49157A (fr) 2014-12-23 2021-06-02 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3359565A1 (en) * 2015-10-09 2018-08-15 Immatics Biotechnologies GmbH Anti-wt1/hla-specific antibodies
IL295398B2 (en) 2015-10-23 2025-01-01 Eureka Therapeutics Inc Antibody/T-cell receptor chimeric constructs and their uses
JP7303750B2 (ja) * 2017-01-24 2023-07-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
KR102412805B1 (ko) * 2017-05-31 2022-06-27 크라제 메디컬 씨오 리미티드 세포 면역 요법을 위한 조성물 및 방법
WO2018225732A1 (ja) * 2017-06-05 2018-12-13 国立大学法人三重大学 Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質
CN111032076A (zh) * 2017-06-14 2020-04-17 阿迪塞特生物公司 能够以hla限制性方式结合hla-a2/tyrd的抗体及其用途
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
MA51302A (fr) * 2017-12-21 2021-03-31 Hoffmann La Roche Anticorps se liant à hla-a2/wt1
EP3755371A4 (en) * 2018-02-23 2021-11-24 Abexxa Biologics, Inc. ANTI-CANCER TREATMENT COMBINED WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
WO2019192972A1 (en) * 2018-04-04 2019-10-10 F. Hoffmann-La Roche Ag Diagnostic assays to detect tumor antigens in cancer patients
EP3802614A1 (en) * 2018-06-04 2021-04-14 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
JP7090204B2 (ja) * 2018-07-19 2022-06-23 イーライ リリー アンド カンパニー 免疫チェックポイントを標的とする二重特異性抗体
CN112638947B (zh) * 2018-08-30 2022-09-30 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
AU2019354395A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
SG11202103235PA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
JP2022523708A (ja) * 2019-01-29 2022-04-26 グリットストーン バイオ インコーポレイテッド 多重特異性結合タンパク質
SG11202109701SA (en) * 2019-03-25 2021-10-28 Univ Health Network T cell receptors and methods of use thereof
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
EP3986938A4 (en) * 2019-06-18 2023-06-28 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof
BR112022001194A2 (pt) * 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
CN110563804A (zh) * 2019-09-19 2019-12-13 河南省农业科学院 基于天然免疫库筛选识别氧氟沙星单链抗体的多肽序列及应用
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
EP4076666A1 (en) * 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
WO2021226063A1 (en) 2020-05-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Car comprising cd28 zeta and cd3 zeta
MX2022014636A (es) * 2020-05-19 2023-02-23 Amgen Inc Construcciones de unión a mageb2.
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
AU2022233285A1 (en) 2021-03-09 2023-10-19 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
KR20240005854A (ko) * 2021-05-04 2024-01-12 리제너론 파아마슈티컬스, 인크. Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도
CN118541382A (zh) * 2021-12-14 2024-08-23 豪夫迈·罗氏有限公司 使用HLA-A2/MAGE-A4 x CD3双特异性抗体和4-1BB(CD137)激动剂治疗癌症
CN120202015A (zh) * 2022-09-14 2025-06-24 Cdr-生物科技股份有限公司 Mage-a4肽双重t细胞衔接子
AR133120A1 (es) * 2023-09-22 2025-08-27 Regeneron Pharma Métodos para obtener moléculas de anticuerpos que se unen a una interfaz péptido-mhc
GB202315181D0 (en) * 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US8258260B2 (en) 1970-02-11 2012-09-04 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
WO1997015597A1 (en) 1995-10-25 1997-05-01 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6710172B1 (en) 1998-10-02 2004-03-23 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20070099182A1 (en) 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20090062512A1 (en) 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DE10313819A1 (de) 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7488793B2 (en) 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
ATE430164T1 (de) 2004-05-26 2009-05-15 Immunocore Ltd Hochaffine telomerase-t-zellen-rezeptoren
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
ES2319286T3 (es) 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2006103429A2 (en) 2005-04-01 2006-10-05 Medigene Limited High affinity hiv t cell receptors
ATE512160T1 (de) 2005-04-26 2011-06-15 Immatics Biotechnologies Gmbh T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
CA2630023A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
AU2007254859A1 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd Antibodies as T cell receptor mimics, methods of production and uses thereof
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20100158927A1 (en) * 2007-03-29 2010-06-24 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
JP5352586B2 (ja) 2007-07-27 2013-11-27 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物
HUE027057T2 (en) 2007-07-27 2016-08-29 Immatics Biotechnologies Gmbh New immunogenic epitope for immunotherapy
CN103911358B (zh) 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
US20110105724A1 (en) 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
WO2009090651A2 (en) 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
PL2113253T3 (pl) 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
HUE024541T2 (hu) 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
US20120077696A1 (en) 2009-03-15 2012-03-29 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
US8933198B2 (en) 2009-03-25 2015-01-13 Altor Bioscience Corporation HIV VPR-specific T cell receptors
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2501722A4 (en) * 2009-11-19 2013-05-01 Univ Singapore METHOD FOR PRODUCING T-CELL-RECEPTOR-SIMILAR MONOCLONAL ANTIBODIES AND APPLICATIONS THEREOF
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
EA201291133A1 (ru) * 2010-04-30 2013-04-30 Алексион Фармасьютикалз, Инк. Антитела, обладающие пониженной иммуногенностью в организме человека
US9821073B2 (en) 2010-12-27 2017-11-21 Apo-T B.V. Polypeptide that binds aberrant cells and induces apoptosis
SG193023A1 (en) 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2015070061A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
EA201391449A1 (ru) * 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
US10946104B2 (en) 2012-01-13 2021-03-16 Apo-Tb.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
CA2934033A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Fc-enhanced anti-wt1/hla antibody
HK1249048A1 (zh) 2015-04-03 2018-10-26 Eureka Therapeutics, Inc. 靶向afp肽/mhc复合体的构建体及其用途
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
CN111032076A (zh) 2017-06-14 2020-04-17 阿迪塞特生物公司 能够以hla限制性方式结合hla-a2/tyrd的抗体及其用途

Also Published As

Publication number Publication date
JP6912392B2 (ja) 2021-08-04
MX394431B (es) 2025-03-24
ES2922236T3 (es) 2022-09-12
CN108025045B (zh) 2022-04-26
AU2016276556B2 (en) 2022-08-11
US20180171024A1 (en) 2018-06-21
JP7147018B2 (ja) 2022-10-04
CN114605547B (zh) 2025-02-25
SG10202007398PA (en) 2020-09-29
WO2016199140A8 (en) 2016-12-29
EP4488293A3 (en) 2025-03-26
MX2017015928A (es) 2018-06-22
CA2987889A1 (en) 2016-12-15
KR20180011275A (ko) 2018-01-31
KR20180012851A (ko) 2018-02-06
IL256178B2 (en) 2024-01-01
JP2022188107A (ja) 2022-12-20
JP2018527884A (ja) 2018-09-27
CN107847569A (zh) 2018-03-27
WO2016199141A3 (en) 2017-01-19
CN114437217A (zh) 2022-05-06
US11001642B2 (en) 2021-05-11
CN114605547A (zh) 2022-06-10
AU2016276556C1 (en) 2023-01-19
EP3302538B1 (en) 2022-02-09
JP7376655B2 (ja) 2023-11-08
US12252547B2 (en) 2025-03-18
CN114437217B (zh) 2025-03-14
EP4039270A9 (en) 2023-03-22
US20210388111A1 (en) 2021-12-16
CA3220475A1 (en) 2016-12-15
JP2024016092A (ja) 2024-02-06
CN108025045A (zh) 2018-05-11
AU2016276555B2 (en) 2022-07-21
WO2016199141A8 (en) 2017-11-16
AU2016276556A1 (en) 2018-01-18
MX2022009493A (es) 2022-12-13
EP4039270A1 (en) 2022-08-10
CA2988270A1 (en) 2016-12-15
NL2014935A (en) 2016-12-12
JP2018526970A (ja) 2018-09-20
AU2022268398A1 (en) 2022-12-15
WO2016199141A2 (en) 2016-12-15
MX2017015801A (es) 2018-08-01
IL256178B1 (en) 2023-09-01
EP3302537A1 (en) 2018-04-11
EP4488293A2 (en) 2025-01-08
EP3302538A2 (en) 2018-04-11
JP2021176861A (ja) 2021-11-11
WO2016199140A1 (en) 2016-12-15
JP7013243B2 (ja) 2022-01-31
IL256178A (en) 2018-02-28
IL304821A (en) 2023-09-01
AU2016276555A1 (en) 2018-01-18
IL256177A (en) 2018-02-28

Similar Documents

Publication Publication Date Title
NL2014935B1 (en) T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) T cell receptor like antibodies having fine specificity
CN106632677B (zh) 对hla-a2呈递的wt1肽特异的t细胞受体样抗体
Dahan et al. T-cell-receptor-like antibodies–generation, function and applications
JP7282760B2 (ja) バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
US20100158927A1 (en) Antibodies, methods and kits for diagnosing and treating melanoma
HK1248255A1 (zh) 靶向ny-eso-1肽/mhc复合物的构建体及其用途
HK40069173A (en) Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
WO2024178334A1 (en) Improved phox2b pc-car generation based on structure and saturation mutagenesis